Schoenherr advises majority shareholder of BIA Separations on sale of its 100% shareholding to Sartorius Stedim Biotech

Schoenherr advised the majority shareholder of purification specialist BIA Separations on the 100% sale of its shareholding to German life science company Sartorius Stedim Biotech. BIA Separations will be merged into Sartorius' subgroup Sartorius Stedim Biotech, for a transaction volume totaling EUR 360 million, of which EUR 240 million will be paid in cash and EUR 120 million in shares. The transaction is another highlight mandate for Schoenherr following numerous successful transaction closings in the past two weeks (Schoenherr advises Bitpanda on its USD 52 million Series A financing round; Schoenherr advises Enery on the acquisition and refinancing of the biggest solar park in Bulgaria; Schoenherr advises listed AddLife on its acquisition of DACH Medical Group; and Schoenherr advises KB SmartSolutions, a.s. on the strategic entry and acquisition of a stake in Platební instituce Roger a.s.).

"The past weeks have been exciting. We are very proud that we were able to successfully advise on this headline deal which shows our strength in high-profile technology transactions," said Schoenherr partner Thomas Kulnigg.

The Sartorius Group is a leading international partner of life science research and of the biopharmaceutical industry. With innovative laboratory instruments and consumables, the Group’s Lab Products & Services Division concentrates on serving the needs of laboratories performing research and quality control at pharma and biopharma companies and those of academic research institutes. In the 2019 fiscal year, the company earned a sales revenue of some EUR 1.83 billion. At the end of 2019, more than 9,000 people were employed at the Group’s approximately 60 manufacturing and sales sites, serving customers around the globe.

BIA Separations is a biotechnology company with its headquarters in Slovenia. It develops and manufactures market-leading products for purification and analysis of large biomolecules, such as viruses, plasmids and mRNA, which are used in cell and gene therapies and other advanced therapies.

The international Schoenherr team advising on the transaction was led by Thomas Kulnigg (partner, Vienna) and Vid Kobe (partner, Slovenia). The Vienna team further consisted of Markus Piuk (partner); Maximilian Nutz (associate); Michael Marschall (attorney at law); Andreas Lengger (associate); Dominik Tyrybon (associate); Sascha Schulz (counsel), Michael Woller (partner) and Sebastian Lukic (associate). The Slovenian team consisted of Peter Gorše (attorney at law); Eva Škufca (partner); Matej Črnilec (attorney at law); Marko Frantar (attorney at law); Bojan Brežan (partner); Jurij Lampič (attorney at law) and Urša Ušeničnik (associate).